Categories: News

Cellebrite Completes Acquisition of Drone Forensics Leader SCG Canada, Inc.

Addition of Unmanned Aerial Vehicle (UAV) forensic capabilities extends Cellebrite’s AI-powered platform to one of the fastest-growing data sources in defense and public safety

- Advertisement -

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 2, 2026 /PRNewswire/ — Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, closed its acquisition of SCG Canada, Inc., a leading provider of hand-held digital forensics solutions that enable access to more than 80 of the most common UAVs. SCG’s solution enables extraction, decoding and visualization of millions of data points from drones that often become key forensic artifacts.

- Advertisement -

Use of drones has continued to expand globally across the defense, intelligence, law enforcement and commercial sectors. At the same time, drones are increasingly used for malicious activity by bad actors. Drones produce a massive number of data points, including flight logs, video files, cell tower connections and many more. SCG’s solution enables rapid access and visualization of mission-critical data at the point of collection, for quick decisions that can save lives. SCG’s powerful drone forensic data extraction capability creates an additional new, rich data source to help power Cellebrite AI, driving better intelligence outcomes for customers. The device’s hand-held portability also presents an opportunity to leverage Cellebrite’s AI for enhanced decision making in the field where speed is essential. For more insights into the drone market and the strategic rationale behind Cellebrite’s acquisition, visit here.

- Advertisement -

“Accessing drone data adds major value to our customers and further amplifies the impact of Cellebrite’s AI-powered platform for multi-data source analysis, a critical component of modern-day investigations and intelligence gathering,” said Thomas E. Hogan, Cellebrite’s chief executive officer. “We are excited to have SCG on board and are thrilled to hear our customers’ enthusiasm of this added capability in support of their missions to enable a safer world.”

- Advertisement -

“We are still just scratching the surface when it comes to what drone data can tell us,” said Brent Salo, SCG’s founder and Cellebrite’s new vice president of drone forensics. “Cellebrite is the perfect home for SCG, as the Company is already a trusted partner and leader in the defense, intelligence and public safety communities.”

- Advertisement -

Financial terms of the deal were not disclosed.

- Advertisement -

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

- Advertisement -

Caution Regarding Forward Looking Statements
This document includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, the growth of the drone market, the value of drone data and customer interest and enthusiasm in the Company’s drone forensics are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s digital investigation solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; Cellebrite’s dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite’s dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

- Advertisement -

About Cellebrite  
Cellebrite’s (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite’s AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate more than 1.5 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite’s technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com/investors and find us on social media @Cellebrite.

- Advertisement -

Media   
Victor Cooper  
Sr. Director of Corporate Communications 
Victor.cooper@cellebrite.com   
+1 404.804.5910 

- Advertisement -

Investor Relations  
Andrew Kramer
Vice President, Investor Relations 
investors@cellebrite.com
+1 973.206.7760 

- Advertisement -

Logo – https://mma.prnewswire.com/media/2855183/Cellebrite_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/cellebrite-completes-acquisition-of-drone-forensics-leader-scg-canada-inc-302699935.html

- Advertisement -

Recent Posts

First Large-Scale Study by AI Search Monitoring Platform OtterlyAI Shows YouTube is #2 Social Platform for AI Citations

First analysis of 100 million AI citations across six platforms shows AI search engines favor…

37 minutes ago

Wix Launches App in ChatGPT, Expanding Website Creation to one of the Worlds Leading Conversational AI Platforms

Users can now generate Wix Harmony websites directly within their ChatGPT conversations NEW YORK –…

37 minutes ago

Verum Messenger Launched Its Own Payment System – Verum Finance

The new functionality expands the capabilities of the messenger, transforming it into a comprehensive digital…

37 minutes ago

The Sigourney Award-2026 Now Accepting Applications for Psychoanalytic Innovation

International Prize Honors Trailblazing Work Advancing Psychoanalytic Thought and Principles — Cash Award and Global…

40 minutes ago

Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies…

40 minutes ago

The largest pharma show in Asia makes its return to Shanghai this June 2026

SHANGHAI, March 2, 2026 /PRNewswire/ -- CPHI & PMEC China 2026 is set to take…

40 minutes ago